Gastroenterological Perspectives on Acute Cardiac Care — the Management of Patients with Implanted Coronary Stents Following an Acute Coronary Syndrome

Anca Negovan 1 , András Mester 2 , and Dan Dumitrașcu 3
  • 1 Clinic of Internal Medicine II, University of Medicine and Pharmacy, Tîrgu Mureș, Romania
  • 2 Clinic of Cardiology, University of Medicine and Pharmacy, Tîrgu Mureș, Romania
  • 3 Clinic of Gastroenterology, “Iuliu Hațieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania

Abstract

Cardiovascular and digestive diseases frequently share the same risk factors such as obesity, unhealthy diet, or several social behaviors, and the increasing prevalence of patients with overlapped cardiovascular and digestive symptoms is a challenging problem in the daily practice. Patients with gastro-esophageal reflux disease can exhibit various forms of chest pain that can be very similar to angina. Furthermore, antithrombotic therapies used for preventive or curative purposes in patients with cardiovascular diseases are frequently associated with gastrointestinal side effects including bleeding. At the same time, in patients with coronary stents presenting to the emergency department with chest pain, angina triggered by stent thrombosis or restenosis should be differentiated from angina-like symptoms caused by a gastrointestinal disease. The aim of this review was to present the complex inter-relation between gastroesophageal diseases and angina in patients on dual antiplatelet therapy following an acute coronary syndrome, with a particular emphasis on the role of anemia resulting from occult or manifest gastrointestinal bleeding, as a precipitating factor for triggering or aggravating angina.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Bhuiya FA, Pitts SR, McCaig LF. Emergency department visits for chest pain and abdominal pain: United States, 1999–2008. NCHS Data Brief. 2010;43:1-8.

  • 2. Fass R, Achem SR. Noncardiac chest pain: epidemiology, natural course and pathogenesis. J Neurogastroenterol Motil. 2011;17:110-123. doi: 10.5056/jnm.2011.17.2.110.

  • 3. Bhatt DL, Scheiman J, Abraham NS, et al. American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation. 2008;118:1894-1909. doi: 10.1161/CIRCULATIONAHA.108.191087.

  • 4. Richter JE. Chest pain and gastroesophageal reflux disease. J Clin Gastroenterol. 2000;30:S39-S41.

  • 5. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology. 2016;150:1368-1379. doi: 10.1053/j.gastro.2016.02.012.

  • 6. Herregods TVK, Bredenoord AJ, Oors JM, Bogte A, Smout AJPM. Determinants of the Association between Non-Cardiac Chest Pain and Reflux. Am J Gastroenterol. 2017;112:1671-1677. doi: 10.1038/ajg.2017.288.

  • 7. Faybush EM, Fass R. Gastroesophageal reflux disease in noncardiac chest pain. Gastroenterol Clin North Am. 2004;33:41-54.

  • 8. Roman C, Bruley des Varannes S, Muresan L, Picos A, Dumitrascu DL. Atrial fibrillation in patients with gastrointestinal reflux disease: a comprehensive review. World J Gastroenterol. 2014; 20:9592-9599. doi: 10.3748/wjg.v20.i28.9592.

  • 9. Anderson JL, Adams CD, Antman EM, et al. American Heart Association Task Force on Practice Guidelines; American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2007;116:e.148e304. doi: 10.1016/j.jacc.2007.02.013

  • 10. Kushner FG, Hand M, Smith Jr SC, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205e41. doi: 10.1016/j.jacc.2009.10.015.

  • 11. Egholm G, Thim T, Madsen M, et al. Gastroscopy-related adverse cardiac events and bleeding complications among patients treated with coronary stents and dual antiplatelet therapy. Endosc Int Open. 2016;4:E527-E533. doi: 10.1055/s-0042-102649.

  • 12. Patrono C, Andreotti F, Arnesen H, et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J. 2011;32:2922-2932. doi: 10.1093/eurheartj/ehr373.

  • 13. Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2018;53:34-78. doi: 10.1093/ejcts/ezx334.

  • 14. Zeymer U, Hohlfeld T, Vom Dahl J, et al. Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE). Thromb Haemost. 2017;117:625-635. doi: 10.1160/TH16-08-0650.

  • 15. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.

  • 16. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189. doi: 10.1056/NEJMoa050522.

  • 17. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366:1607-1621. doi: 10.1016/S0140-6736(05)67660-X.

  • 18. Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967-1974. doi: 10.1016/S0140-6736(09)61751-7.

  • 19. Negovan A, Iancu M, Moldovan V, et al. The contribution of clinical and pathological predisposing factors to severe gastro-duodenal lesions in patients with long-term low-dose aspirin and proton pump inhibitor therapy. Eur J Intern Med. 2017;44:62-66. doi: 10.1016/j.ejim.2017.05.017.

  • 20. Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708-1713, 1713a-1713b. doi: 10.1093/eurheartj/eht042.

  • 21. Negovan A, Iancu M, Moldovan V, et al. Clinical Risk Factors for Gastroduodenal Ulcer in Romanian Low-Dose Aspirin Consumers. Gastroenterol Res Pract. 2016;2016:7230626. doi: 10.1155/2016/7230626.

  • 22. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917. doi: 10.1056/NEJMoa1007964.

  • 23. Gargiulo G, Costa F, Ariotti S, et al. Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY trial. Am Heart J. 2016;174:95-102. doi: 10.1016/j.ahj.2016.01.015.

  • 24. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost. 2009;101:714-719.

  • 25. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51:256-260. doi: 10.1016/j.jacc.2007.06.064.

  • 26. Simon N, Finzi J, Cayla G, et al. Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokineticpharmacodynamic relationships in stable coronary artery disease patients. Eur J Clin Pharmacol. 2015;71:1059-1066. doi: 10.1007/s00228-015-1882-3.

  • 27. Negovan A, Voidăzan S, Pantea M, et al. The AGT A-20 C gene polymorphism is associated with ulcer in Romanian patients treated with low-dose aspirin. Rev Romana Med Lab. 2015;23:179-187. doi: https://doi.org/10.1515/rrlm-2015-0017.

  • 28. Furtado RH, Giugliano RP, Strunz CM, et al. Drug Interaction Between Clopidogrel and Ranitidine or Omeprazole in Stable Coronary Artery Disease: A Double-Blind, Double Dummy, Randomized Study. Am J Cardiovasc Drugs. 2016;16:275-284. doi: 10.1007/s40256-016-0172-5.

  • 29. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015;10:e0124653. doi: 10.1371/journal.pone.0124653.

  • 30. Sherwood MW, Melloni C, Jones WS, et al. Individual Proton Pump Inhibitors and Outcomes in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy: A Systematic Review. J Am Heart Assoc. 2015;4: e002245. doi: 10.1161/JAHA.115.002245.

  • 31. Ng SC, Chan FK. NSAID-induced gastrointestinal and cardiovascular injury. Curr Opin Gastroenterol. 2010;26:611-617. doi: 10.1097/MOG.0b013e32833e91eb.

  • 32. Berger PB, Bhatt DL, Fuster V, et al. CHARISMA Investigators. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation. 2010;121:2575-2583. doi: 10.1161/CIRCULATIONAHA.109.895342.

  • 33. Valkhoff VE, Sturkenboom MC, Kuipers EJ. Risk factors for gastrointestinal bleeding associated with low-dose aspirin. Best Pract Res Clin Gastroenterol. 2012;26:125-140. doi: 10.1016/j.bpg.2012.01.011.

  • 34. Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111:705-710. doi: 10.1016/j.jfma.2011.11.028.

  • 35. Sengupta N, Tapper EB, Patwardhan VR, et al. Risk Factors for Adverse Outcomes in Patients Hospitalized With Lower Gastrointestinal Bleeding. Mayo Clin Proc. 2015;90:1021-1029. doi: 10.1016/j.mayocp.2015.04.024.

  • 36. Aoki T, Nagata N, Niikura R, et al. Recurrence and mortality among patients hospitalized for acute lower gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2015;13:488-494. doi: 10.1016/j.cgh.2014.06.023.

  • 37. Shaukat A, Waheed S, Alexander E, et al. Etiology of gastrointestinal bleeding in patients on dual antiplatelet therapy. J Dig Dis. 2018;19:66-73. doi: 10.1111/1751-2980.12575.

  • 38. Nagata N, Niikura R, Aoki T, et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc. 2014;80:1124-1131. doi: 10.1016/j.gie.2014.06.039.

  • 39. Abdel Samie A, Theilmann L. Endoscopic procedures in patients under clopidogrel/dual antiplatelet therapy: to do or not to do? J Gastrointestin Liver Dis. 2013;22:33-36.

  • 40. Carlin N, Asslo F, Sison R, Shaaban H, Baddoura W, Manji F, Depasquale J. Dual Antiplatelet Therapy and the Severity Risk of Lower Intestinal Bleeding. J Emerg Trauma Shock. 2017;10:98-102. doi: 10.4103/JETS.JETS_110_15.

  • 41. Oakland K, Desborough MJ, Murphy MF, Schachter M, Jairath V. Re-bleeding and Mortality After Lower Gastrointestinal Bleeding in Patients Taking Anti-platelets or Anti-coagulants. Clin Gastroenterol Hepatol. 2017;pii:S1542-3565(17)31528-8. doi: 10.1016/j.cgh.2017.12.032.

  • 42. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482.

  • 43. Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735-1749. doi: 10.1001/jama.2016.3775.

  • 44. Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025-1034. doi: 10.1016/S0140-6736(17)30397-5.

  • 45. Christ M, Popp S, Pohlmann H, et al. Implementation of high sensitivity cardiac troponin T measurement in the emergency department. Am J Med. 2010;123:1134-1142. doi: 10.1016/j.amjmed.2010.07.015.

  • 46. Erhardt L, Herlitz J, Bossaert L, et al. Task force on the management of chest pain. Eur Heart J. 2002;23:1153-1176.

  • 47. Bruno RR, Donner-Banzhoff N, Söllner W, et al. The Interdisciplinary Management of Acute Chest Pain. Dtsch Arztebl Int. 2015;112:768-779; quiz 780. doi: 10.3238/arztebl.2015.0768.

  • 48. Schüepp M, Ullmer E, Weinbacher M, et al. Chest pain early after percutaneous coronary intervention: incidence and relation to ECG changes, cardiac enzymes and follow-up events. J Invasive Cardiol. 2001;13:211-216.

  • 49. Kini AS, Lee P, Mitre CA, Duffy ME, Sharma SK. Postprocedure chest pain after coronary stenting: implications on clinical restenosis. J Am Coll Cardiol. 2003;41:33-38.

  • 50. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56:1897-907. doi: 10.1016/j.jacc.2010.07.028.

  • 51. Marino BC, Nascimento GA, Rabelo W, et al. Clinical Coronary In-Stent Restenosis Follow-Up after Treatment and Analyses of Clinical Outcomes. Arq Bras Cardiol. 2015;104:375-386. doi: 10.5935/abc.20140216.

  • 52. Magalhaes MA, Minha S, Chen F, et al. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circ Cardiovasc Interv. 2014;7:768-776. doi: 10.1161/CIRCINTERVENTIONS.114.001341.

  • 53. Chang C, Chen Y, Ong E, et al. Chest pain after percutaneous coronary intervention in patients with stable angina. Clin Interv Aging. 2016;11:1123-1128. doi: 10.2147/CIA.S103605.

  • 54. Giustino G, Kirtane AJ, Baber U, et al. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016;117:1877-1883. doi: 10.1016/j.amjcard.2016.03.034.

  • 55. Casado Arroyo R, Polo-Tomas M, Roncales MP, et al. GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. Heart. 2012;98:718-723. doi: 10.1136/heartjnl-2012-301632.

  • 56. García Rodríguez LA, Lin KJ, Hernández-Díaz S, Johansson S. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123:1108-1115. doi: 10.1161/CIRCULATIONAHA.110.973008.

  • 57. González-Pérez A, Sáez ME, Johansson S, Himmelmann A, García Rodríguez LA. Risk of bleeding after hospitalization for a serious coronary event: a retrospective cohort study with nested case-control analyses. BMC Cardiovasc Disord. 2016;16:164. doi: 10.1186/s12872-016-0348-6.

  • 58. Veitch AM. Endoscopy in Patients on Antiplatelet Agents and Anticoagulants. Curr Treat Options Gastroenterol. 2017;15:256-267. doi: 10.1007/s11938-017-0137-z.

  • 59. Eisenberg MJ, Richard PR, Libersan D, et al. Safety of shortterm discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation. 2009;119:1634-1642. doi: 10.1161/CIRCULATIONAHA.108.813667.

  • 60. Sumayin Ngamdu K, El Mallah W, et al. One-Year Survival is Not Affected by Gastrointestinal Bleeding After Percutaneous Coronary Interventions. Am J Med Sci. 2017;353:381-386. doi: 10.1016/j.amjms.2017.01.017.

  • 61. Guo Y, Wei J. Clinical outcomes of various continued antiplatelet therapies in patients who were administered DAPT following the implantation of drug-eluting stents and developed gastrointestinal hemorrhage. Exp Ther Med. 2016;12:1125-1129. doi: 10.3892/etm.2016.3378.

  • 62. Jensen BES, Hansen JM, Larsen KS, et al. Randomized clinical trial: the impact of gastrointestinal risk factor screening and prophylactic proton pump inhibitor therapy in patients receiving dual antiplatelet therapy. Eur J Gastroenterol Hepatol. 2017;29:1118-1125. doi: 10.1097/MEG.0000000000000934.

  • 63. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3:231-241. doi: 10.1016/S2468-1253(18)30037-2.

  • 64. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, lowdose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834-839. doi: 10.1056/NEJM200009213431202.

  • 65. Fletcher EH, Johnston DE, Fisher CR, et al. Systematic review: Helicobacter pylori and the risk of upper gastrointestinal bleeding risk in patients taking aspirin. Aliment Pharmacol Ther. 2010;32:831-839. doi: 10.1111/j.1365-2036.2010.04415.x.

  • 66. Sostres C, Gargallo CJ, Lanas A. Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. World J Gastroenterol. 2014;20:9439-9450. doi: 10.1016/j.bpg.2012.01.006.

  • 67. Leung Ki EL, Chan FK. Interaction of Helicobacter pylori infection and low-dose aspirin in the upper gastrointestinal tract: implications for clinical practice. Best Pract Res Clin Gastroenterol. 2012;26:163-172. doi: 10.3748/wjg.v20.i28.9439.

  • 68. Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111:705-710. doi: 10.1016/j.jfma.2011.11.028.

  • 69. Ayada K, Yokota K, Kobayashi K, Shoenfeld Y, Matsuura E, Oguma K. Chronic infections and atherosclerosis. Ann N Y Acad Sci. 2007;1108:594-602.

  • 70. Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. J Dig Dis. 2012;13:342-349. doi: 10.1111/j.1751-2980.2012.00599.x.

  • 71. Liu J, Wang F, Shi S. Helicobacter pylori Infection Increase the Risk of Myocardial Infarction: A Meta-Analysis of 26 Studies Involving more than 20,000 Participants Helicobacter. 2015;20:176-183. doi: 10.1111/hel.12188.

  • 72. Kanbay M, Gur G, Yucel M, Yilmaz U, Muderrisoglu H. Helicobacter pylori seroprevalence in patients with coronary artery disease. Dig Dis Sci. 2005;50:2071-2074. doi: 10.1007/s10620-005-3009-7.

  • 73. Lee M, Baek H, Park JS, et al. Current Helicobacter pylori infection is significantly associated with subclinical coronary atherosclerosis in healthy subjects: A cross-sectional study. PLoS One. 2018;13:e0193646. doi: 10.1371/journal.pone.0193646.

  • 74. Huang KW, Luo JC, Leu HB, et al. Risk factors for upper gastrointestinal bleeding in coronary artery disease patients receiving both aspirin and clopidogrel. J Chin Med Assoc. 2013;76:9-14.

OPEN ACCESS

Journal + Issues

Search